GSK Opens Singapore Plant To Produce Pneumonia Vaccines
This article was originally published in PharmAsia News
Executive Summary
U.K.-based GlaxoSmithKline plans to produce vaccines in Singapore to prevent bacteria that cause pneumonia. The plans were announced at an opening of a $411 million Singapore plant, which is to be tested for up to two years before beginning vaccine production in 2011. The intent is to produce pneumococcal conjugate vaccine for children under 2 years old. GSK introduced the vaccine in the United States in 2000 and it has since shown to be effective in reducing the number of pneumococcal cases in children. (Click here for more
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.